The first BTK inhibitor approved for use in the clinic was Ibrutinib; a small molecule initially described as a high affinity BTK inhibitor [13] and subsequently shown to be effective in animal models of autoimmune disease and B-cell lymphoma [14]. Here, BTK is linked to B-cell non-Hodgkin lymphoma.